ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
Interim Safety Analysis Supports Continuation Of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial Of PDX In Patients With Peripheral T-cell Lymphoma
Allos
Therapeutics, Inc. (Nasdaq: ALTH) announced that an independent Data
Monitoring Committee (DMC) has completed the pre-specified 65-patient
safety review of data from the Company's pivotal Phase 2 PROPEL trial of
PDX (pralatrexate) in patients with relapsed or refractory peripheral
T-cell lymphoma (PTCL), and has recommended that the trial continue per the
protocol. This interim assessment was based upon an evaluation of patients
enrolled in the study who completed at least one cycle of treatment with
PDX. The Company currently expects to complete patient enrollment in the
PROPEL study in the second quarter of 2008.
"The DMC recommendation represents another important milestone in the
development of a potential new treatment option for patients with relapsed
or refractory peripheral T-cell lymphoma, a patient population for which
there are currently no approved agents," said Pablo J. Cagnoni, M.D.,
Senior Vice President and Chief Medical Officer of Allos. "We remain
pleased with the progress of the PROPEL trial and look forward to
continuing to drive our PDX product development and commercialization plans
in 2008."
PROPEL (Pralatrexate in Patients with Relapsed Or Refractory PEripheral
T-cell Lymphoma) is a pivotal Phase 2, international, multi-center,
open-label, single-arm study that will seek to enroll a minimum of 100
evaluable patients with relapsed or refractory PTCL who have progressed
after at least one prior treatment. Patients receive 30 mg/m2 of PDX once
every week for six weeks followed by one week of rest per cycle of
treatment. The primary efficacy endpoint of the study is objective response
rate (complete and partial response). Secondary efficacy endpoints include
duration of response, progression-free survival and overall survival.
Owen A. O'Connor, MD, PhD, Director, Lymphoid Development & Malignancy
Program and Chief, Lymphoma Service, Columbia University, Herbert Irving
Comprehensive Cancer Center, New York, is the international study chair.
In accordance with the PROPEL study design, in January 2007, the DMC
completed an interim analysis of safety data based on the first 10 patients
enrolled to the study who completed at least one cycle of treatment with
PDX, and recommended that the trial continue per the protocol. Also in
accordance with the study design, in September 2007, an interim analysis of
patient response and safety data was conducted based on the first 35
patients enrolled to the study who completed at least one cycle of
treatment with PDX. The results of the interim analysis of patient response
data exceeded the pre-specified threshold for continuation of the trial,
which required a minimum of four responses (complete or partial) out of the
first 35 evaluable patients, as determined by independent oncology review.
In addition, the DMC identified no major safety concerns and recommended
that the trial continue per the protocol.
The PROPEL trial is being conducted under an agreement with the United
States Food and Drug Administration (FDA) under its special protocol
assessment (SPA) process. The SPA process allows for FDA evaluation of a
clinical trial protocol intended to form the primary basis of an efficacy
claim in support of an NDA, and provides an agreement that the study
design, including trial size, clinical endpoints and/or data analyses are
acceptable to the FDA. The FDA granted orphan drug designation to PDX for
the treatment of T-cell lymphoma in July 2006 and granted fast track
designation to PDX for the treatment of patients with T-cell lymphoma in
September 2006. In April 2007, the Commission of the European Communities,
with a favorable opinion of the Committee for Orphan Medicinal Products of
the European Medicines Agency, or EMEA, granted orphan medicinal product
designation to PDX for the treatment of patients with PTCL
About the Data Monitoring Committee (DMC)
The DMC is comprised of independent medical experts and was established
by Allos as part of the Company's compliance with good clinical practice
guidelines. The DMC is responsible for monitoring the on-going safety of
patients participating in the PROPEL trial and for conducting formal
interim safety assessments of trial results.
About Peripheral T-cell Lymphoma
Peripheral T-cell lymphomas, or PTCLs, are a biologically diverse and
uncommon group of blood cancers that account for approximately 10% to 15%
of all cases of non-Hodgkin's lymphoma, or about 7,100 patients annually.
The average five-year survival rate for PTCL patients is approximately 25%.
There are currently no pharmaceutical agents approved for use in the
treatment of either first-line or relapsed or refractory PTCL.
About PDX (pralatrexate)
PDX is a novel, small molecule chemotherapeutic agent that inhibits
dihydrofolate reductase, or DHFR, a folic acid (folate)-dependent enzyme
involved in the building of nucleic acid, or DNA, and other processes. PDX
was rationally designed for efficient transport into tumor cells via the
reduced folate carrier, or RFC-1, and effective intracellular drug
retention. The Company believes these biochemical features, together with
preclinical and clinical data in a variety of tumors, suggest that PDX may
have a favorable safety and efficacy profile relative to methotrexate and
certain other DHFR inhibitors.
About Allos Therapeutics, Inc.
Allos Therapeutics is a biopharmaceutical company focused on the
development and commercialization of small molecule therapeutics for the
treatment of cancer. The Company's lead product candidate, PDX
(pralatrexate), is a novel antifolate currently under evaluation in a
pivotal Phase 2 (PROPEL) trial in patients with relapsed or refractory
peripheral T-cell lymphoma. The PROPEL trial is being conducted under an
agreement reached with the U.S. Food and Drug Administration under its
special protocol assessment, or SPA process. The Company is also
investigating PDX in patients with non-small cell lung cancer and a range
of lymphoma sub-types. The Company's other product candidate is RH1, a
targeted chemotherapeutic agent currently being evaluated in a Phase 1
trial in patients with advanced solid tumors or non-Hodgkins Lymphoma
(NHL). For additional information, please visit the Company's website at
http://www.allos.com.
Safe Harbor Statement
This press release contains forward-looking statements that are made
pursuant to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Such forward-looking statements include statements
relating to the potential safety and efficacy profile of PDX relative to
methotrexate and certain other DHFR inhibitors, the potential safety and
efficacy of PDX for the treatment of PTCL or any other type of cancer; the
Company's projected timeline for completing enrollment in the PROPEL trial;
and other statements that are other than statements of historical facts. In
some cases, you can identify forward-looking statements by terminology such
as "may," "will," "should," "expects," "intends," "plans," anticipates,"
"believes," "estimates," "predicts," "projects," "potential," "continue,"
and other similar terminology or the negative of these terms, but their
absence does not mean that a particular statement is not forward-looking.
Such forward-looking statements are not guarantees of future performance
and are subject to risks and uncertainties that may cause actual results to
differ materially from those anticipated by the forward-looking statements.
These risks and uncertainties include, among others: that the Company may
experience delays in the conduct or completion of the PROPEL trial, whether
caused by competition, adverse events, patient enrollment rates, regulatory
issues or other factors; that clinical trials may not demonstrate that PDX
is both safe and effective for the treatment of patients with PTCL or any
other type of cancer; that data from preclinical studies and clinical
trials may not be indicative of future clinical trial results; that the
safety and/or efficacy results of the PROPEL trial may not support an
application for marketing approval in the United States or any other
country; that an application for marketing approval may not be accepted for
priority review or at all by the FDA or any other regulatory authority; and
that the Company may lack the financial resources and access to capital to
fund future clinical trials for PDX or any of its other product candidates.
Additional information concerning these and other factors that may cause
actual results to differ materially from those anticipated in the
forward-looking statements is contained in the "Risk Factors" section of
the Company's Annual Report on Form 10-K for the year ended December 31,
2006 and in the Company's other periodic reports and filings with the
Securities and Exchange Commission. The Company cautions investors not to
place undue reliance on the forward-looking statements contained in this
press release. All forward-looking statements are based on information
currently available to the Company on the date hereof, and the Company
undertakes no obligation to revise or update these forward-looking
statements to reflect events or circumstances after the date of this
presentation, except as required by law.
The Allos logo is a trademark of Allos Therapeutics, Inc.
Allos Therapeutics, Inc.
http://www.allos.com
Interimare de siguranþã Analiza sprijinã Continuarea Allos terapeutice "pivot Faza 2 propulsa proces al PDX periferice la pacienþii cu T-cell Lymphoma - Interim Safety Analysis Supports Continuation Of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial Of PDX In Patients With Peripheral T-cell Lymphoma - articole medicale engleza - startsanatate